RootsAnalysis is pleased to announce the publication of its recent study, titled, “Bispecific Antibody Therapeutics Market (4th Edition), 2020-2030.”
Thereport features an extensive study of the current market landscape, offering aninformed opinion on the likely adoption of these therapeutics over the nextdecade. The study features an in-depth analysis, highlighting the capabilitiesof various stakeholders engaged in this domain. Amongst other elements, thereport includes:
· A detailed assessment of the current marketlandscape of drug developers engaged in the development of bispecific antibodytherapeutics.
· A comprehensive analysis of novel technologyplatforms that are either currently available or being developed for thegeneration of bispecific antibody therapeutics.
· Detailed profiles of marketed and clinicalstage (phase II and phase III) bispecific antibody therapeutics.
· Key takeaways from the bispecific antibodytherapeutics pipeline.
· An analysis of the initiatives of bigbiopharma players engaged in this domain.
· An analysis of recent partnerships andcollaboration agreements inked in bispecific antibody therapeutics domain.
· A review on the key steps involved andchallenges associated with the manufacturing of bispecific antibodies.
· A clinical trial analysis of ongoing andplanned studies related to bispecific antibody therapeutics.
· A review of the key promotional strategiesthat have been adopted by the developers of the marketed bispecific antibodies.
· A discussion on important, industry-specifictrends, key market drivers and challenges, under a SWOT framework.
GetCustomized Report: https://www.rootsanalysis.com/reports/286/request-customization.html
Adetailed market forecast, featuring analysis of the current and projectedfuture opportunity across key market segments (listed below)
TargetDisease Indication
· Autoimmune Disorders
· Eye Disorders
· Genetic Disorders
· Hematological Malignancies
· Infectious Diseases
· Inflammatory Disorders
· Skin Disorders
Mechanismof Action
· Cytokines Retargeting / Neutralization
· Dual Ligands Blocking
· T-cell Retargeting / Activation
· Others
TargetAntigens
· CD3 x CD19
· CD30 x CD16A
· Factor IXa x Factor X
· IL-1α x IL-1β
· IL-13 x IL-4
· IL-17A x Albumin
· IL-17A x IL-17F
· Psl x PcrV
· TNF-α x HAS
· VEGF-A x ANG2
· Others
AntibodyFormat
· Asymmetric
· Fragments
· Symmetric
· Others
KeyGeographical Region
· North America
· Europe
· Asia-Pacific
Transcriptsof interviews held with the following senior level representatives ofstakeholder companies:
· Martin Steiner (Chief Executive Officer,Synimmune)
· Ludger Große-Hovest (Chief ScientificOfficer, Synimmune)
· Jane Dancer (Chief Business Officer, F-Star)
· Siobhan Pomeroy (Senior Director, BusinessDevelopment, Cytom X)
· Yinjue Wang (Associate Director, ProcessDevelopment, Innovent Biologics)
Keycompanies covered in the report
· Amgen
· Ablynx
· AbbVie
· Affibody
· Affimed
· Alphamab
· AstraZeneca
· Avillion
· Chugai Pharmaceuticals
· Eddingpharm
· GSK
· Merck
· Merus
· Roche
· Regeneron Pharmaceuticals
· Taisho Pharmaceuticals
· Zymeworks
Requestfor PDF Sample
https://www.rootsanalysis.com/reports/286/request-sample.html
AboutRoots Analysis
RootsAnalysis is one of the fastest growing marketresearch companies, sharing fresh and independent perspectives in thebio-pharmaceutical industry. The in-depth research, analysis and insights aredriven by an experienced leadership team which has gained many years ofsignificant experience in this sector. If you’d like help with your growingbusiness needs, get in touch at info@rootsanalysis.com
ContactInformation
RootsAnalysis Private Limited
GauravChaudhary
+1(415) 800 3415
Gaurav.Chaudhary@rootsanalysis.com
